Hua Jin

10PUBLICATIONS
36CO-AUTHORS
HaematologyHaematological tumoursTraditional Chinese medicine and treatmentsImmunogenetics (incl. genetic immunology)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|May 28, 2025
High-dose cytarabine with idarubicin consolidation for acute myeloid leukemia in first complete remission: a randomized controlled trial.

Yu Zhang, Zinan Feng, Jing Du

|May 21, 2025
Venetoclax plus azacitidine with or without homoharringtonine followed by allogeneic haematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukaemia: A multicentre cohort study.

Yiling Ye, Xinyu Liu, Huajuan Dai

|Nov 16, 2024
A prophylactic tyrosine kinase inhibitor strategy based on measurable residual disease pre-transplantation for Ph+ acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation: A prospective multicenter cohort study.

Hui Liu, Hui Xu, Peiru Chi

|Nov 12, 2024
Homoharringtonine Added to Venetoclax and Azacitidine Improves Outcome and Mitigates Genetic Impact in Relapsed/Refractory AML: A Multicenter Cohort Study.

Guopan Yu, Yu Zhang, Sijian Yu

|Sep 30, 2024
Prognostic impact of IL7R mutations on acute myeloid leukemia.

Qiqi Tao, Qiaoyuan Wu, Yutong Xue

|Feb 09, 2024
Clinical and genetic characteristics predict outcomes of acute myeloid leukemia patients with FLT3 mutations receiving venetoclax-based therapy.

Guangyang Weng, Jingya Huang, Na An

Pageof 2

Frequent Collaborators

5 joint publications

Qifa Liu

4 joint publications

Li Xuan

3 joint publications

Guopan Yu

2 joint publications

Xuejie Jiang